|
|
Post by brentie on Feb 24, 2018 21:36:17 GMT -5
|
|
|
|
Post by centralcoastinvestor on Feb 24, 2018 22:28:37 GMT -5
What a crap article. It’s not even close to being balanced. The article basically talks about alleged cancer links to Exubera that were never really proven but makes it sound as though they were. Then equates Exubera with Afrezza. I would love to know who funded this.
|
|
|
|
Post by sportsrancho on Feb 24, 2018 23:04:15 GMT -5
Mannkind better get on this right away they need an apology and a retraction!
Plus there is another link that leads to a worse article:-(
|
|
|
|
Post by gamblerjag on Feb 24, 2018 23:14:16 GMT -5
where it's a bummer that this was even written this will get buried so quickly. this is not a doctor endocrinologist or anybody of importance. This will be forgotten as quickly as the yellow cards we were getting from aegis capital. If this is big Pharma paying someone to write an article like this and this is your best shot… We're golden |
|
|
|
Post by sportsrancho on Feb 24, 2018 23:28:53 GMT -5
where it's a bummer that this was even written this will get buried so quickly. this is not a doctor endocrinologist or anybody of importance. This will be forgotten as quickly as the yellow cards we were getting from aegis capital. If this is big Pharma paying someone to write an article like this and this is your best shot… We're golden Thanks gamblerjag, you’re right:-) |
|
|
|
Post by celo on Feb 25, 2018 0:28:48 GMT -5
No one should even click on the link. Don't give it the time of day
|
|
|
|
Post by kc on Feb 25, 2018 12:46:54 GMT -5
What is the date of this article? It appears to be very misleading and I cannot find a date. I am sure that this will be addressed by MannKind and Dr. Kendall if this is a new article. For some reason it seems I have seen this in the past |
|
|
|
Post by sportsrancho on Feb 25, 2018 15:33:50 GMT -5
What is the date of this article? It appears to be very misleading and I cannot find a date. I am sure that this will be addressed by MannKind and Dr. Kendall if this is a new article. For some reason it seems I have seen this in the past kc I don’t remember reading this before. And right, there is no date? There is a 2014 date on this... Afrezza is not the first inhaled insulin to come to market. Between September 2006-October 2007, Pfizer marketed Exubera, an inhaled insulin that may have caused lung cancer. The risk of lung cancer was more than five times as high in diabetic patients who took this product, and this did not occur only in cigarette smokers, although a smoking history appeared to greatly increase the likelihood of lung cancer developing. It’s important to note that insulin acts in the body not only to lower blood glucose levels, but also as a growth-promoting hormone. Lung cancer cells appear to be more sensitive to such effects than normal lung cells, and there is no doubt that with inhaled insulin the lungs are exposed to much higher insulin concentrations than those seen in people not taking insulin injections, or those seen after insulin injections. Exubera also reduced the lung’s ability to exchange oxygen and carbon dioxide, the pulmonary diffusing capacity, to a greater extent. Exubera was withdrawn voluntarily from the market by Pfizer, its manufacturer, and we do not know whether the cancer risk was real, or whether, if it exists, it would apply to Afrezza. At the FDA advisory committee presentation on Afrezza, it was estimated that a randomized clinical trial to detect risk of lung cancer doubling with this treatment would require more than 60,000 participants, followed for many years. So, it’s fair to say that we are a long way from really knowing about Afrezza and long term cancer risk What’s the bottom line? Inhaled insulin works. Many people who need to take insulin might find it much more comfortable to take a “puff” than a “shot” before meals. This could lead to more use of insulin where it is needed, and to better control of diabetes. However, inhaled insulin causes cough, although this tends to improve over time. It causes some reduction in lung function – and we just do not know whether an adverse effect in less than one in ten people over short term studies will more commonly lead to such effects over years of clinical use. More worrisome, another similar product appears to have increased lung cancer. Will I prescribe Afrezza for people with diabetes? Not a lot, and not for past or present smokers, and not for people with any breathing problems (or heart issues that might cause difficulty breathing), and not without getting pulmonary function testing and explaining all of what I see as potential risks, and not without close follow-up. But some people who need insulin just cannot bring themselves to inject it, and, for a few of these, recognizing the potential for harm, Afrezza might still be a good answer. Author image Dr. Zachary Bloomgarden Dr. Bloomgarden has a national reputation for writing and lecturing nationally and internationally on diabetes, and has authored some 300 publications in this field. He is Clinical Professor in the Department of Medicine, Division of Endocrinology, Mount Sinai School of Medicine, as well as participating in teaching rounds in the Departments of Pediatrics and Medicine. TAGS: AFREZZA, ORAL INSULIN |
|
|
|
Post by hillsave on Feb 28, 2018 9:26:26 GMT -5
I’ve been using Afrezza for ny T2 for 34 months and I have had no problems at all. I’ve been checked by almost every kind of medical device and my lungs are great.
|
|
|
|
Post by digger on Feb 28, 2018 9:54:17 GMT -5
I’ve been using Afrezza for ny T2 for 34 months and I have had no problems at all. I’ve been checked by almost every kind of medical device and my lungs are great. How much afrezza do you use daily? |
|
/production/original_573352236.gif)
